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Background: The utility of heated and humidified high-flow nasal oxygen (HFNO) for severe COVID-19-
related hypoxaemic respiratory failure (HRF), particularly in settings with limited access to intensive care
unit (ICU) resources, remains unclear, and predictors of outcome have been poorly studied.
Methods: We included consecutive patients with COVID-19-related HRF treated with HFNO at two tertiary
hospitals in Cape Town, South Africa. The primary outcome was the proportion of patients who were success-
fully weaned from HFNO, whilst failure comprised intubation or death on HFNO.
Findings: The median (IQR) arterial oxygen partial pressure to fraction inspired oxygen ratio (PaO2/FiO2) was
68 (5492) in 293 enroled patients. Of these, 137/293 (47%) of patients [PaO2/FiO2 76 (6393)] were success-
fully weaned from HFNO. The median duration of HFNO was 6 (39) in those successfully treated versus 2
(15) days in those who failed (p<0.001). A higher ratio of oxygen saturation/FiO2 to respiratory rate within
6 h (ROX-6 score) after HFNO commencement was associated with HFNO success (ROX-6; AHR 0.43,
0.310.60), as was use of steroids (AHR 0.35, 95%CI 0.190.64). A ROX-6 score of 3.7 was 80% predictive of
successful weaning whilst ROX-6  2.2 was 74% predictive of failure. In total, 139 patents (52%) survived to
hospital discharge, whilst mortality amongst HFNO failures with outcomes was 129/140 (92%).
Interpretation: In a resource-constrained setting, HFNO for severe COVID-19 HRF is feasible and more almost
half of those who receive it can be successfully weaned without the need for mechanical ventilation.
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Coronavirus disease 2019 (COVID-19) is a potentially fatal infec-
tion caused by the novel severe acute respiratory syndrome
Research in Context
Evidence before this study
The utility of high-flow nasal oxygen (HFNO) for severe Coronavi-
rus disease 2019 (COVID-19)-related hypoxaemic respiratory fail-
ure (HRF), particularly in settings with limited access to intensive
care unit (ICU) resources, remains unclear. We searched PubMed
and Google Scholar for articles published in all languages up to 25
July 2020 using the search terms “HFNO”, “HFNC”, “COVID-1900,
“respiratory failure”, “ARDS”, “ICU”, “mechanical ventilation”, and
“outcomes”. We identified only 4 studies (2 in non-peer-reviewed
preprint format) that evaluated HFNO in COVID-19-related HRF.
The four studies together included a total of 312 patients, all were
retrospective, and only one study enroled patients from a
resource-limited setting (China). Significantly, none were from
HIV-endemic or resource-poor (African) settings, and none evalu-
ated the effect of steroids in modulating outcomes, which is now
the standard of care.
Added value of this study
To our knowledge this is the largest prospective observational
study to evaluate HFNO for severe COVID-19 pneumonia. We
showed that HFNO in combination is feasible and can success-
fully be utilised to provide respiratory support to a significant
proportion of patients with COVID-19-related HRF. Moreover,
this approach avoided mechanical ventilation even in patients
with profound hypoxaemia. A higher ROX index measured at
6 h after HFNO initiation (ROX-6), along with treatment with
steroids, independently predicted success. The majority of our
patients received HFNO in a ward-based non-critical care envi-
ronment, demonstrating the feasibility of HFNO outside of the
ICU using affordable pulse oximetry-based monitoring.
Implications of all the available evidence
In a resource-constrained setting, HFNO for severe COVID-19 HRF
is feasible andmore almost half of those who receive it can be suc-
cessfully weaned without the need for mechanical ventilation.
2 G.L. Calligaro et al. / EClinicalMedicine 28 (2020) 100570coronavirus-2 (SARS-CoV-2) [1]. The highly contagious nature and
exponential spread of SARS-CoV-2, coupled with its potential for a
rapid progression to acute respiratory distress syndrome (ARDS), has
overwhelmed health care systems globally, contributing to the high
mortality rates in early reports [1,2].
The initial approach for respiratory support for severe COVID-19
pneumonia centred around invasive mechanical ventilation and the
standard lung protective strategy recommended for ARDS [3]. This
may have been detrimental to a proportion of patients due to ventila-
tor induced lung injury (VILI) and associated systemic inflammation
[4]. Furthermore, other strategies to improve oxygenation may be
more appropriate in patients with hypoxemic respiratory failure who
do not require ventilatory support [4].
High-flow nasal oxygen (HFNO) is delivered by an air/oxygen
blender, an active humidifier, a single heated circuit, and a nasal inter-
face. It delivers adequately heated and humidified medical gas at flow-
rates of up to 60 L/min, and is considered to have a number of physio-
logical benefits, including the reduction of anatomical dead space and
work of breathing, the provision of a constant fraction of inspired oxy-
gen with adequate humidification and a degree of positive end-expira-
tory pressure (PEEP) [5,6]. Although HFNO was originally utilised in
neonatology, its use has extended to adult critical care [6].
The Western Cape Province was the initial epicentre of the out-
break in South Africa, which by early September 2020 was the countrywith the seventh highest number of confirmed COVID-19 cases world-
wide [7]. The ratio of ICU to hospital beds in the public health sector in
South Africa is only ~4% [8]. In April 2020, in anticipation of the rapid
saturation of the existing critical care capacity resources, the two
major tertiary centres in Cape Town adopted the use of HFNO, both
inside the intensive care unit (ICU) and in non-critical care environ-
ments, in an effort to increase the capacity to manage patients with
severe respiratory failure secondary to COVID-19 [9].
To date, few retrospective studies with limited sample sizes, one
of which is from a relatively resource-limited setting (China), have
evaluated HFNO in COVID-19-related HRF [1013]. However, to
what extent HFNO is feasible in a more resource-poor, HIV-endemic,
and non-ICU setting, remains unclear. Moreover, the predictors of
treatment failure and the modulating effect of steroids thereon
remain unclarified. We hypothesised that a significant proportion of
patients with hypoxemic respiratory failure could be supported with
HFNO as initial support, thereby decreasing the burden on our
healthcare system’s intensive care platform during the COVID-19
pandemic. Thus, the main aim of this study was to assess the impact
of HFNO in avoiding mechanical ventilation in patients with severe
respiratory failure secondary to COVID-19. As secondary objectives,
we aimed to identify potential physiological parameters or bio-




We conducted a prospective multi-centre observational study
within the public health system in Cape Town, South Africa. The
study was approved by the local ethics committees at each site (UCT
HREC 295/2020 and SU HREC S20/05/001_COVID-19), and informed
consent was waived in acknowledgement that the intervention was
being assessed within the routine service. The study is reported in
accordance with the STROBE statement for cohort studies [14] (Sup-
plementary Appendix).
2.2. Setting
The study was conducted at two urban tertiary academic hospitals
in Cape Town, South Africa [Groote Schuur Hospital (GSH) and Tyger-
berg Hospital (TBH)], servicing a population of ~4.5 million with high
tuberculosis and HIV prevalence [15]. Patients were enroled from the
19th of April to the 30th of June 2020. During this period, each hospi-
tal admitted ~1520 COVID-19 positive patients per day. At the end
of the study period, GSH had admitted 1342 patients with COVID-19,
and had increased ICU bed capacity three-fold to 55 beds, admitting
~2530 ventilated patients to ICU per week during the peak (all
HFNO being offered in repurposed medical wards) [16,17]; at TBH,
1016 patients with COVID-19 were admitted during the study period,
ICU bed capacity had tripled to 45 beds, and ~25 patients were admit-
ted to ICU (both ventilated and for HFNO) per week during the peak
(personal communication, Directorate of Health Impact Assessment,
Western Cape Government: Health).
2.3. Participants
Eligible participants were consecutive adult patients (aged 18
years) with severe respiratory failure, and laboratory-confirmed
COVID-19 pneumonia [detection of SARS-CoV-2 by real-time reverse
transcription polymerase chain reaction (RT-PCR) on any respiratory
sample] who were treated with HFNO during hospitalisation. Severe
respiratory failure was defined as a respiratory rate 30 breaths per
minute with oxygen saturations 92% despite oxygen at 15 L/min via
reservoir bag, and/or arterial oxygen partial pressure to fractional
G.L. Calligaro et al. / EClinicalMedicine 28 (2020) 100570 3inspired oxygen (PaO2/FiO2) ratio<150. The decision to initiate HFNO
was at the discretion of the treating clinical team based on a protocol
for the stepwise escalation of oxygen therapy, and was contraindi-
cated in patients with exhaustion or confusion. Likewise, the decision
of the timing of intubation and mechanical ventilation was not proto-
colised, but determined by the treating clinical team, and guided by a
composite assessment of respiratory effort, patient exhaustion, rising
arterial partial pressure of carbon dioxide (PaCO2) or altered mental
state rather than a single measure of oxygenation alone such as satu-
ration or PaO2. Awake prone positioning was encouraged at every
clinical encounter and reinforced by nursing staff according to a
shared clinical protocol.
Therapeutic interventions like anticoagulation strategy and the
use of steroids (both physician directed) were also recorded. No other
SARS-CoV-2 directed therapy was provided to any patient, either off-
label or as part of a clinical trial, at either hospital during the study
period. The start of the study predated the preliminary report of the
efficacy of dexamethasone by RECOVERY [18], and prescription of
corticosteroids prior to this date was by physician preference. After
the 16th of June, all patients on HFNO received either dexamethasone
6 mg intravenously daily, or prednisone 40 mg daily, for 10 days.3. HFNO
Heated and humidified HFNO was exclusively provided within the
ICU at TBH, and within designated medical wards (non-ICU) at GSH
where patients were cohorted. Patients wore surgical masks and all
personnel were supplied with personal protective equipment,Fig. 1. CONSORT diagram showing outcomes of HFNO and survival to discharge.
HFNO: high-flow nasal cannula oxygen; ICU: intensive care unit; MV: mechanical ventila
Success = weaned from HFNO; Failure= need for intubation or death.
* Triaged due local facility protocol, DNR order or pre-specified patient preference.
y Survival to hospital discharge = 139/269 (52%): denominator excludes those still in hosp
yy Sudden death = abrupt unexpected death on HFNO (intubation was not being considerincluding N95 masks and visors. HFNO was delivered either by a
Hamilton C1 ventilator (Hamilton Medical AG, Bonaduz, Switzer-
land), Airvo࣪ 2 (Fisher & Paykel Healthcare, Irvine, California, USA) or
Inspire࣪ O2FLO (Vincent Medical, Hong Kong, China) machine. Flow
was initiated at 5060 L/min with FiO2 0.81.0, titrated to aim for an
oxygen saturation (SpO2) 92%.
3.1. Procedures
Demographic and clinical variables, and if available, contempora-
neous peripheral blood differential counts and inflammatory bio-
markers (D-dimer and C-reactive protein) were recorded on
commencement of HFNO. HFNO settings (FiO2 and flow rate) along
with heart rate, respiratory rate and peripheral oxygen saturations
were recorded at 6 h post-initiation of HFNO. Using these variables,
we calculated the validated ROX score [19] (ratio of oxygen satura-
tion/FiO2 to respiratory rate) at 6 h (ROX-6) and modified ROX score
[20] (ROX score divided by heart rate) at 6 h (mROX-6) score. For
patients who were intubated before 6 h, the variables at the time that
the decision was made that HFNO was failing were recorded.3.2. Outcomes
The primary endpoint was the proportion of patients with a suc-
cessful outcome (weaned off HFNO). Failure was defined as compos-
ite of the need for intubation or death whilst on HFNO. Of secondary
interest were predictors of HFNO failure, and survival to hospital dis-
charge (percentage of patients discharged home alive, or transferredtion, DNR: do not resuscitate.
ital or ventilated in ICU (n = 24).
ed at the time).
Table 1
Patient characteristics.
Total (n = 293) Failure (n = 156) Success (n = 137) P-value
Age (years)
Median (IQR) 52 (4458) 53 (4458) 50 (4457) 0.187
Sex
Males, n (%) 163 (56) 84 (54) 79 (58) 0.512
Diabetes
Any diabetes, n (%) 158 (54) 82 (53) 76 (55) 0.697
Poorly controlled (HbA1c8%), n (%) 79 (27) 46 (29) 33 (24) 0.299
HbA1c, median (IQR) 9.3 (7.111.4) 9.6 (7.911.5) 8.75 (711.3) 0.259
Hypertension
n (%) 131 (45) 72 (46) 59 (43) 0.562
BMI (kg/m2)
25, n (%) 31 (11) 13 (8) 18 (13) 0.182
2530, n (%) 109 (37) 65 (42) 44 (32) 0.092
3035, n (%) 94 (32) 55 (35) 39 (28) 0.214
35, n (%) 59 (20) 23 (15) 36 (26) 0.021
HIV status
Negative, n (%) 211 (72) 116 (74) 95 (69) 0.340
Positive, n (%) 45 (15) 22 (14) 23 (17) 0.525
Unknown, n (%) 37 (13) 18 (12) 19 (4) 0.549
CD4 count (if HIV+ve) (cells/m3)
Median (IQR) 309 (146441) 284 (145388) 335 (267455) 0.355
ART use (vs. no ART if HIV+ve)
n (%) 36 (80) 19 (86) 17 (74) 0.230
Duration of symptoms prior to HFNO
Days, median (IQR) 7 (49) 7 (59) 7 (48) 0.107
Modified SOFA score y, y
35 276 (95) 146 (94) 131 (96) 0.390
>5 14 (5) 9 (6) 5 (4) 0.390
Creatinine (mmol/L)
Median (IQR) 80 (63100) 81 (64103) 77 (6393) 0.261
PaO2/FiO2 ratio at HFNO initiation yy
mmHg, median (IQR) 68 (5492) 63 (5183) 76 (58102) <0.001
Anticoagulation with LWMH*
None, n (%) 2 (1) 1 (1) 1 (1) 1.000
Prophylactic, n (%) 10 (3) 3 (2) 7 (5) 0.198
Therapeutic, n (%) 281 (96) 152 (97) 129 (94) 0.237
Steroid treatmenty
n (%) 222 (76) 103 (66) 119 (88) <0.001
ICU setting (vs. medical ward)
n (%) 105 (36) 44 (28) 61 (45) 0.004
Lymphocyte count (x109/L)yy
Median (IQR) 1.18 (0.891.58) 1.15 (0.921.57) 1.23 (0.831.62) 0.561
C-reactive protein (mg/L)yy
Median (IQR) 184 (11310) 235 (142344) 173 (105274) 0.002
D-dimer (mg/L)yy
Median (IQR) 0.83 (0.412.54) 1.03 (0.494.44) 0.56 (0.361.78) 0.002
Note: HFNO = high flow nasal cannula; ICU = intensive care unit; IQR = interquartile range; HIV = human immuno-
deficiency virus; ART = antiretroviral treatment; BMI = body mass index; SOFA = Sequential Organ Failure Assess-
ment; PaO2/FiO2 = ration of arterial partial pressure of oxygen to inspired oxygen fraction; LMWH = low-molecular
weight heparin; CRP = C-reactive protein.
* Prophylactic = 0.5 mg/kg enoxaparin daily; therapeutic = 1 mg/kg enoxaparin twice daily (dose adjusted for
renal impairment where necessary).
y Dexamethasone 6 mg or prednisone 40 mg daily for 10 days.
yy n = 290,250, 249, 197 and 240 for mSOFA, PaO2/FiO2 ratio at HFNO initiation, lymphocyte count, C-reactive
protein and D-dimer results respectively.
4 G.L. Calligaro et al. / EClinicalMedicine 28 (2020) 100570to a rehabilitation facility, excluding patients still admitted and
undergoing treatment).
3.3. Statistical analysis
Categorical variables were expressed as frequencies and percen-
tages, andwere compared using Pearson’s x2tests or Fisher’s exact tests.
Continuous variables were expressed as means with standard devia-
tions, or medians with inter-quartile ranges. Non-parametric data was
compared using Wilcoxon rank-sum tests. A CONSORT diagram
reported the flow of patients in the study (Fig. 1). The crude cumulative
proportion of HFNO success was calculated. Predictors of intubation
were primarily analysed using a Cox proportional hazards model, incor-
porating clinically important variables selected a priori for the model.
The index date was the date of initiation of HFNO, with censoringoccurring upon intubation, death, or the end of the study (30th June
2020). Receiver operating characteristic (ROC) curves were constructed
using the software program GraphPad Prism (version 8, GraphPad Soft-
ware, USA) and Youden’s index was calculated to determine the cut-off
that maximised sensitivity and specificity for ROX-6 and mROX-6. [21]
Descriptive statistics, comparisons between parametric and non-
parametric samples, and Cox proportional hazards regression were per-
formed using Stata (V.12.1, Stata Corp, College Station, Texas, USA) [22].
3.4. Role of the funding source
The funder of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report. The
first and last authors had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
Fig. 2. Proportion of patients on HFNO reaching outcome per day of therapy.
The median (IQR) duration of HFNO was 6 (39) days in those successfully treated versus 2 (15) days in those who failed (p<0.001).
*P<0.05 when compared to proportion of previous day for same outcome (Pearson’s x2 test).
Table 2
Oxygen requirement and respiratory parameters after 6 h on HFNO.
Total (n = 293) Failure (n = 156) Success (n = 137) P-value
SpO2 (%)
Median (IQR) 90 (8694) 89 (8392) 91 (8994) <0.001
FiO2 (%)
Median (IQR) 90 (8595) 90 (9095) 90 (8093) <0.001
Respiratory rate (breaths/mins)
Median (IQR) 37 (3043) 40 (3446) 32 (2840) <0.001
Heart rate (beats/mins)
Median (IQR) 101 (90108) 104 (92110) 97 (88105) <0.001
SpO2/FiO2 ratio
Median (IQR) 100 (93107 98 (89103) 104 (98115) <0.001
ROX index at 6 h (ROX-6)
Median (IQR) 2.78 (2.253.62) 2.41 (2.063.05) 3.26 (2.724.10) <0.001
Modified ROX index at 6 h (mROX-6)
Median (IQR) 2.90 (2.163.74) 2.33 (1.923.12) 3.44 (2.674.20) <0.001
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4.1. Patient population
Two hundred and ninety-three patients were enroled between
the 16th of April and 30th of June 2020: 105 (36%) were admitted
to the ICU for HFNO, while 188 (64%) received HFNO in the desig-
nated COVID-19 ward (non-ICU). The median (IQR) age was 52
(4458) years; 163/292 (56%) were males. Every patient was on
via reservoir face mask at 15 L/min prior to initiation of HFNO; the
median (IQR) ratio of PaO2/FiO2 pre-HFNO was 68 (5492). The
median (IQR) duration of symptoms prior to treatment with HFNO
was 7 (49) days. Comorbidities were highly prevalent: 134/293
(46%) patients were diabetic (with 79/134 (59%) having an
HbA1c>8%); 131/293 (45%) were hypertensive, 153/293 (52%)
were obese (body mass index30), and 45/292 (15%) were HIV
positive (Table 1). Therapeutic anticoagulation with enoxaparin at
1 mg/kg 12-hourly was almost universal (281/293, 96%), and 222/
293 (76%) received steroids (dexamethasone or prednisolone /
hydrocortisone dose-equivalent). Most patients (188/293, 64%)
were treated with HFNO outside of the ICU. At any point during
the study period, between 25 and 40 patients were being treated
with HFNO at each of the participating hospitals.4.2. Primary outcome
Successful treatment with HFNO was achieved in 137/293 (47%) of
patients (Fig. 1); of these, the majority (128/137, 93%) were subse-
quently discharged from hospital. At the time of writing, 8 patients
(6%) had been weaned off HFNO but were still in hospital. The median
(IQR) duration of HFNOwas 6 (39) days in those successfully treated
versus 2 (15) days in those who failed (p<0.001 (Fig. 2). Of the lat-
ter, time to intubation was 2 (0.55) days, whilst time to death on
HFNO was 4 (26) days (p = 0.02).
4.3. Predictors of HFNO failure
Differences in demographics, clinical characteristics and inflam-
matory marker profiles between patients with a successful outcome
on HFNO and those with HFNO failure are summarised in Table 1.
Patients who had a successful outcome on HFNO had higher oxygen
saturations, lower respiratory and heart rates, and lower oxygen
requirements (FiO2) within 6 h of commencement of HFNO (Table 2).
ROX-6 and mROX-6 were also significantly different amongst
patients with HFNO failure vs. success: 2.41 (2.063.05) vs. 3.26
(2.724.10) for ROX-6 (p<0.001) and 2.33 (1.923.12) vs. 3.44
(2.674.20) for mROX-6 (p<0.001), respectively (Fig. S1,
Table 3
Predictors of HFNO failure.
Variable N Estimated HR* (95% CI) P-value Adjusted HRy (95% CI) P-value
Age (per year increase) 293 1.00 (0.991.02) 0.795
Male (vs. females) 293 0.95 (0.701.29/) 0.749
HIV status (vs. negative)
Positive 45 0.75 (0.481.19) 0.224
Hypertension 131 0.99 (0.731.34) 0.930
Diabetes*
Well-controlled (vs. no diabetes) 55 0.97 (0.631.50) 0.883 1.27 (0.812.00) 0.301
Poorly controlled (vs. no diabetes) 79 1.31 (0.931.88) 0.143 1.56 (1.062.28) 0.023
Obesity (BMI 30 kg/m2 vs. <30 kg/m2) 153 0.80 (0.581.09) 0.158
mSOFA (per 1 point increase) 290 1.18 (1.041.36) 0.054
Duration of symptoms (per 1 day increase) 293 1.02 (0.981.06) 0.313
Treatment with steroids 221 0.31 (0.220.44) 0.001 0.25 (0.180.37) <0.001
ICU setting (vs. medical ward) 105 0.68 (0.480.97) 0.032
ROX-6 score (per 1 point increase) 279 0.46 (0.370.58) <0.001 0.42 (0.330.53) <0.001
mROX-6 score (per 1 point increase) 277 0.51 (0.420.61) <0.001
Lymphocyte count (per 1 £ 109 increase) 249 1.19 (0.921.52) 0.181
CRP (vs.<100 mg/L) 38
100199 66 0.71 (0.381.30) 0.269
200299 50 0.88 0.461.70) 0.712
300399 31 1.14 (0.592.20) 0.701
400499 15 1.54 (0.703.38) 0.280
500 7 2.99 (1.237.25) 0.015
D-dimer (vs. <1.5 mg/L) 150
1.515.0 39 1.48 (0.932.36) 0.097
5 42 1.99 (1.283.12) 0.002
Note: HR = hazard ratio; CI = confidence interval; HIV = human immunodeficiency virus; mSOFA = Modified Sequential Organ Fail-
ure Assessment, ICU = intensive care unit; CRP = C-reactive protein.
* Well controlled = HbA1c8%; poorly-controlled = HbA1C>8%.
y ROX-6 used in adjusted model rather than mROX because of similar HR and diagnostic performance (see Fig. S2, Supplementary
Appendix) with fewer input variables than mROX-6.
zBest model fit obtained with inclusion of steroid use, diabetes (poorly-controlled vs. no diabetes), and ROX-6.
6 G.L. Calligaro et al. / EClinicalMedicine 28 (2020) 100570Supplementary Appendix). 17/293 (6%) patients failed HFNO before
6 h, and had ROX-6 and mROX-6 scores recorded at the time of intu-
bation.
ROX-6 and mROX-6 were very closely correlated (r2=0.870), and
both had virtually identical hazard ratios for outcome in univariable
analysis (Table 3), so ROX-6 was chosen for the multivariable analysis
as it includes one less observation and is easier to calculate. In this
model, only poorly-controlled diabetes (HbA1c>8%) (adjusted HR
1.56, 95% CI 1.062.28), treatment with steroids (adjusted HR 0.25,
95% CI 0.180.37,), ROX-6 score (adjusted HR 0.42, 95% CI 0.330.54)
were significantly associated with the relative hazard of treatment
failure. The association between treatment with steroids and ICU set-
ting was significant (p = 0.004), suggesting that the influence of set-
ting on outcome was largely explained by the increased use of
steroids in ICU.
4.4. Diagnostic performance of ROX-6 for HFNO failure
The area under the ROC curve (AUC) was 0.75 (Fig. 3A). A ROX-6
below 3.7 (cut-off A, maximising sensitivity) was 90% sensitive (true
positives) whilst ROX-6 above 2.2 (cut-off B, maximising specificity)
was 90% specific (true negatives) (Fig. 3B). The corresponding positive
predictive values (PPV) and negative predictive values (PPV) are
shown in the table below Fig. 3. The single cut-off that maximised
sensitivity and specificity (Youden’s index) was 2.7; the PPV and NPV
at Youden’s index was 72% and 73%, respectively.
4.5. Survival to hospital discharge
At the time of analysis, 10/293 (3%) patients were still in the ICU
and ventilated, and 14/293 (5%) were still in hospital after either suc-
cessful HFNO treatment or ICU discharge. Overall survival to hospital
discharge for patients treated with HFNO (denominator excluding
those still in hospital or ventilated in ICU) was 139/269 (52%), and
mortality was 130/269 (48%). In patients successfully treated withHFNO, one patient (1/137, 1%) died after successfully being weaned
off HFNO. Of the patients who failed HFNO, 111/156 (71%) were intu-
bated after failing HFNO, and 45/156 (29%) died whilst receiving the
therapy. Of the deaths prior to intubation, 26/45 (58%) died unex-
pectedly before intubation could be considered, and the remaining
19/45 (42%) were assessed as requiring intubation but were declined
as non-ICU candidates due local facility protocols, or in a few cases,
had pre-specified their preference not to be intubated. Survival to
hospital discharge was 128/129 (99%) and 11/140 (7%) in the HFNO
success and failure groups respectively (p<0.0001).
5. Discussion
This prospective observational study of HFNO for severe COVID-
19 pneumonia is the largest reported to date. Our study showed that
HFNO can successfully be utilised to provide respiratory support to
patients with COVID-19 pneumonia and HRF, and avoided mechani-
cal ventilation even in patients with profound hypoxaemia. However,
HFNO failed in just over half of our cohort, and the mortality in this
group of patients who received mechanical ventilation was very
high. Although these poorer ventilation outcomes may be the conse-
quence of a patient population suffering from socioeconomic depri-
vation, multiple comorbidities and high tuberculosis and HIV
prevalence, it also raises the possibility that persistence with HFNO
in certain patients may delay the inevitable requirement for intuba-
tion, which could jeopardise clinical outcomes [23]. This further high-
lights the need for early differentiation of patients who may benefit
from HFNO from those who will require mechanical ventilation,
although in our resource-limited setting access to the latter was not
unrestricted. We showed that a higher ROX index measured at 6 h
after HFNO initiation (ROX-6), along with treatment with steroids,
independently predicted success. Moreover, poorly controlled diabe-
tes was associated with HFNO failure. Importantly, treatment with
HFNO outside of the ICU, and HIV positive status, did not portend
worse outcome.
Fig. 3. A. Receiver operating characteristic (ROC) curve for ROX-6 for predicting HFNO failure. ROC was performed for ROX-6 (134 patients successfully treated with HFNO and
145 patients who failed HFNO). Area under the curve (AUC) for ROX-6 is 0.75 with p<0.0001. B. Scatter plot of ROX score (ratio of oxygen saturation/FiO2 to respiratory rate) at 6 h
(ROX-6) showing cut-offs maximising sensitivity and specificity.
PPV = positive predictive value; NPV = negative predictive value.
A ROX-6 below 3.7 (cut-off A, maximising sensitivity) was 90% sensitive (true positives) whilst ROX-6 above 2.2 (cut-off B, maximising specificity) was 90% specific (true nega-
tives). The single cut-off that maximised sensitivity and specificity (Youden’s index) was 2.7; the PPV and NPV at Youden’s index was 72% and 73%, respectively.
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based environment, demonstrating the feasibility of HFNO outside of
the ICU. This potential to increase the capacity to manage severe
COVID-19 pneumonia in resource-constrained settings has important
implications. In settings where firstly, access to the infrastructure
and/or expertise of ICU care is limited, or, secondly, transport of clini-
cally unstable patients to a facility with a designated ICU is poten-
tially hazardous and undesirable, HFNO may be considered as an
appropriate mode of respiratory support. While adequate PPE is man-
datory for all health care workers attending to patients on HFNO, evi-
dence suggest that the risk of airborne transmission is no greater
than the use of face mask oxygen [24]. The degree to which HFNO
can be scaled up as a treatment for large numbers of patients with
HRF would, however, be highly dependant on local oxygen capacity,
the delivery infrastructure within individual hospitals, and the
robustness of the supply chain.Evidence of efficacy of HFNO in reducing the requirement for intu-
bation is consistent with previous studies, albeit in patients with HRF
of other causes [25,26]. A meta-analysis of 9 randomised controlled
trials of acute HRF in the pre-COVID-19 era found HFNO resulted in
lower intubation rates without affecting survival [27]. Preliminary
data, mainly case reports and small case series, have also described
its potential utility in patients with COVID-19 pneumonia
[9,10,2832], and usually in combination with awake proning
[33,34]. The finding that ROX and mROX can be used as a prediction
tool is also consistent with studies of early predictors of HFNO out-
come in other forms of respiratory failure [19,20]. We found that
ROX performed equivalently to mROX, and thus favoured it, as it
comprised fewer input variables. In a 2-year multicentre prospective
observational cohort study of 191 patients with pneumonia (not
related to COVID-19) treated with HFNO, Roco et al. found that 68
(35.6%) required intubation [15]. The prediction accuracy of the ROX
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0.703; 12 h, 0.759). ROX 4.88 measured at 2 (hazard ratio, 0.434;
95% CI, 0.2640.715; P = 0.001), 6 (hazard ratio, 0.304; 95% CI,
0.1820.509; P < 0.001), or 12 h (hazard ratio, 0.291; 95% CI,
0.1610.524; P < 0.001) after HFNO initiation was associated with a
lower risk for intubation. A ROX <2.85, <3.47, and <3.85 at 2, 6, and
12 h of HFNO initiation, respectively, were predictors of treatment
failure. They found that amongst components of the index, oxygen
saturation as measured by pulse oximetry/FiO2 had a greater weight
than respiratory rate.
A recently published letter from France (n = 62) [11], two pre-
print reports from the same centre in the USA (n = 104 and n = 129)
and a study from China (n = 17) [10] evaluated COVID-19 pneumonia
treated with HFNO. They found intubation rates of between 31% and
66%, and that ROX (measured within the first 4 h) predicted success
[11]. Compared to our study, there were several important differen-
ces in the published French study: the median ROX score that pre-
dicted survival was 1.5 times higher than ROX-6; time to intubation
was much shorter (10 h), and ICU mortality was much lower i.e. 17%.
The obvious distinction was the severity of HRF: the mean SPO2 was
substantially lower (90 vs 96%) and respiratory rate higher (37 vs 25
per min) in our study population.
The main strengths of this study are the prospective, multi-centre
design, the relatively large sample size with completed outcomes col-
lected over a relatively short period of time, and the reporting predic-
tors and outcomes within the context of corticosteroids, which is
now the standard of care. The latter is an important point because it
will likely impact thresholds for intubation and outcomes including
death. In addition, we also clarified the relative importance of the dif-
ferent predictors including the components of the ROX score. It is
also the only study from a population with high HIV prevalence, and
the first report of the large-scale use of HFNO outside of a standard
ICU. The compromise of providing non-invasive respiratory support
outside of a conventional ICU setting has been made in other places
(such as in Italy [35]  however, these patients were still cared for by
intensivists in designated “level 200 ICU beds).
Some limitations of this study deserve emphasis. We could not
adequately control for differences in physician experience and judge-
ment around the timing of intubation. However, well-outlined proto-
colised provincial guidelines for intubation and mechanical
ventilation, including score-based risk stratification (based on SOFA
score, pre-morbid status, comorbidities and age) were followed [36].
Studies utilising composite physiological scores to determine predic-
tors for the need for intubation inherently suffer from confirmation
bias [19,20,37,38], as even if the ROX index is not formally calculated,
the individual components (SpO2, FiO2 and respiratory rate) are
incorporated in a Bayesian-type reasoning by the clinician in
making the intubation decision. Nevertheless, an objective measure
that crystallises the current respiratory parameters, and can poten-
tially reassure the clinician about the safety of continuing with
HFNO, is still useful. Biomarker data was incomplete, thus reducing
the power of the multivariable prediction model. However,
this was a pragmatic ‘real-world’ study where blood sampling
was clinically driven rather than protocolised outside the
ICU. Our study was also not randomised (with a “usual care” as
an alternative) but this would have been impractical given the
scale of the pandemic and the limited intensive care resources.
Lastly, intermittent proning was routinely performed, making it
impossible to determine the impact of HFNO without prone
positioning.
In conclusion, in a resource-constrained setting where access to
ICU care and mechanical ventilation is limited, HFNO for severe
COVID-19 HRF is feasible and deliverable even in a ward-based non-
critical care environment, and more almost half of those who receive
it can be successfully weaned without the need for mechanical venti-
lation. Conversely, mortality in patients who fail HFNO is high.Declaration of Competing Interest
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